Summary
In vivo and in vitro experiments have shown that nicotinamide enhances the regeneration of rat B cells. Nicotinamide has been administered to human subjects at a dose of 3 g/day for more than one year without any serious side effects. A trial was conducted to study if nicotinamide could protect B cells in Type I (insulin-dependent) diabetic patients with established diabetes, but still with residual insulin secretion, the latter being evaluated throughout the study period. A randomized double-blind study was carried out on 26 Type I diabetic patients aged 15 to 40 years who had been treated with insulin for 1 to 5 years but who had a residual insulin secretion characterized by a glucagon stimulated C-peptide level higher than 0.1 nmol/l. They were given either 3 g/day of nicotinamide or a placebo for nine months. At baseline the treated and control groups did not differ according to age, diabetes duration, insulin dose, HbA1c or C-peptide levels. Three patients dropped out of the study. At 9 months there were no significant changes in the insulin doses required. However, HbA1c rose in the control group (8.1±0.4 vs 9.8±0.5%, p<0.05) but not in the nicotinamide treated group (7.5±0.5 vs 6.9±0.4%). Insulin secretion deteriorated in the control patients (fasting C-peptide: 0.28±0.05 vs 0.12±0.03 nmol/l, p<0.05; post glucagon C-peptide: 0.34±0.07vs 0.14±0.02, p<0.05) but not in the treated patients (fasting C-peptide: 0.22±0.04 vs 0.24±0.05 nmol/l; post glucagon C-peptide: 0.30±0.04 vs 0.33±0.07). At six and nine months, fasting and stimulated C-peptide were higher in the treated than in the non-treated group. The C-peptide response to a meal test gradually declined in the placebo group, whereas it was stable in the nicotinamide treated group. No serious side effects were noted; in particular, hepatic function and plasma lipid content remained unchanged. These results suggest that nicotinamide treatment may protect residual B-cell function in Type 1 diabetes; but further studies are needed to assess the clinical implications of such treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Eisenbarth GS (1986) Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 314: 1360–1368
Stauffacher W, Burr I, Gutzeit A, Beaven D, Velinsky J, Renold AE (1970) Streptozotocin diabetes: time course of irreversible B-cell damage; further observations on prevention by nicotinamide. Proc Soc Exp Biol Med 133: 194–200
Yonemura Y, Takashima T, Miwa K, Miyazadi I, Yamamoto H, Okamoto H (1984) Amélioration of diabetes mellitus in partially depancreatized rats by poly (ADP-ribose) synthetase inhibitors. Evidence of islet B-cell regeneration. Diabetes 33: 401–404
Yamada K, Nonaka K, Hanafusa T, Miyazaki A, Toyoshima H, Tarvis S (1982) Preventive and therapeutic effects of large dose nicotinamide injections on diabetes associated with insulitis. An observation in non obese diabetic (NOD) mice. Diabetes 31: 749–753
Rossini AA, Like AA, Chick WL, Appel MC, Cahill GF (1977) Studies of streptozotocin-induced insulitis and diabetes. Proc Nat Acad Sci USA 74: 2485–2489
Nomikos IN, Prowse SJ, Carotenuto P, Lafferty KJ (1986) Combined treatment with nicotinamide and desferrioxamine prevents islet allograft destruction in NOD mice. Diabetes 35: 1302–1304
Hawkins DR (1968) Treatment of schizophrenia based on the medical model. J Schizophr 2: 3–10
Hoffer A (1969) Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. Schizophrenia 1: 78–87
The Coronary Drug Project Research Group (1975) Clofibrate and Niacin in coronary heart disease. J Am Med Assoc 231: 360–381
Ma A, Medenica M (1983) Response of generalized granuloma annulare to high dose Nicotinamide. Arch Dermatol 119: 836–839
Vague P, Vialettes B, Lassmann-Vague V, Vallo JJ (1987) Nicotinamide may extend remission phase in insulin-dependent diabetes. Lancet I: 619–620
Mirouze J, Selam JL, Pham TL, Mendoza A, Orsetti A (1978) Sustained insulin induced remissions of juvenile diabetes by means of an artificial pancreas. Diabetologia 14: 223–227
Vague P, Vialettes B, Lassmann V, Moulin JP, Mercier P (1985) Sustained initial remission induced by intensive insulin treatment in type I diabetes. Possible role of the genetic background. Acta Diabetol Lat 21: 295–304
Mistura L, Beccaria L, Meschi F, Flores D'Arlais A, Pellini C, Puzzovio M, Chiumello G (1987) Prednisone treatment in newly diagnosed type I diabetes children: 1-year follow-up. Diabetes Care 10: 38–43
Sochett EB, Daneman D, Clarson C, Ehrlich RM (1987) Factors affecting and patterns of residual insulin secretion during the first year of Type 1 (insulin-dependent) diabetes mellitus in children. Diabetologia 30: 453–459
The DCCT Research Group (1987) Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual B-cell function: observation during eligibility testing for Diabetes control and complications trial (DCCT). J Clin Endocrinol Metab 65: 30–36
Kaneto T (1974) Radioimmunoassay of human proinsulin C-peptide using synthetic human connecting peptide. Endocrinol Jpn 21: 141–150
Irvine WJ, Mc Callum CJ, Gray RS, Campbell CJ, Duncan LJP, Farquhar JW, Vaughan EH, Morris PJ (1977) Pancreatic islet cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease and HLA type. Diabetes 26: 138–147
Madsbad S, Faber OK, Binder C, McNair P, Christiansen C, Transbol I (1978) Prevalence of residual Beta-cell function in insulin dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 27 [Suppl 1]: 262–264
Madsbad S, Krarup T, Regeur L, Faber OK, Binder C (1981) Effect of strict blood glucose control on residual B-cell function in insulin-dependent diabetics. Diabetologia 20: 530–534
Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark Å, Sundkvist G, Thalme B (1988) Factors influencing the magnitude, duration and fall of B-cell function in Type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31: 664–669
Mandfield-Jones S, Jones SK, Peach RDG (1987) Nicotinamide treatment in diabetes. Br J Dermatol 116: 277
Dulin WE, Wyse DM (1969) Studies on the ability of compounds to block the diabetogenic activity of streptozotocin. Diabetes 18: 458–466
Pont A, Rubino JM, Bishop D, Peal R (1979) Diabetes mellitus and neuropathy following vacor ingestion in man. Arch Intern Med 139: 185–187
Okamoto H (1981) Regulation of proinsulin synthesis in pancreatic islets and a new aspect to insulin dependent diabetes. Mol Cell Biochem 37: 43–61
Uchigata Y, Yamamoto H, Nagai H, Okamoto H (1983) Effect of poly (ADP-ribose) synthetase inhibitor administration to rats before and after injection of alloxan and streptozotocin on islet proinsulin synthesis. Diabetes 32: 316–318
Sandler S, Andersson A (1986) Long-term effects of exposure of pancreatic islets to nicotinamide in vitro on DNA synthesis, metabolism and B-cell function. Diabetologia 29: 199–202
Sjöberg S, Gunnarson R, Gjötteberg M, Lefvert AK, Persson A, Östman J (1987) Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 30: 208–213
Fukuda M, Tanaka A, Tamara Y, Ikegami H, Yamamoto Y, Kumamara Y, Smima K (1988) Correlation between minimal secretory capacity of pancreatic B-cells and stability of diabetic control. Diabetes 37: 81–88
Winter SL, Boyer JL (1979) Hepatic toxicity from large doses of vitamin B 3 (Nicotinamide). N Engl J Med 283: 1180–1182
Yamagami T, Miwa A, Takasawa S, Yamamoto H, Okamoto H (1985) Induction of rat pancreatic B-cell tumors by the combined administration of streptozotocin or alloxan and poly (ADP-ribose) synthetase inhibitors. Cancer Res 45: 1845–1849
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vague, P., Picq, R., Bernal, M. et al. Effect of nicotinamide treatment on the residual insulin secretion in Type 1 (insulin-dependent) diabetic patients. Diabetologia 32, 316–321 (1989). https://doi.org/10.1007/BF00265549
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00265549